GLPwatch
Use of tirzepatide (Mounjaro) in type 2 diabetes management: an overview.
Nurs Stand · 2025
Last updated 2026-05-28Tirzepatide (Mounjaro) is a newer medication for type 2 diabetes, used alongside lifestyle changes like diet and exercise. It works by helping the body manage blood sugar levels, though the exact method is explained in the article. The drug is given by injection, with dosing details and possible side effects discussed, as well as situations where it should not be used.
AI summary of the abstract below.
| Journal | Nurs Stand, 2025 |
|---|---|
| Citations | 1 |
| Molecules | tirzepatide |
| Conditions studied | Type 2 Diabetes |
Abstract
Diabetes mellitus is an increasingly common long-term metabolic disease. There are many treatment options available to manage type 2 diabetes and reduce the risk of associated long-term microvascular and macrovascular complications. The management of type 2 diabetes initially focuses on lifestyle changes, such as a healthy diet and increased physical activity levels, with pharmacological intervention used as an adjunct where necessary. Tirzepatide, sold under the brand name Mounjaro, is the latest pharmacological therapy to be developed for this condition. This article discusses the place of tirzepatide therapy as part of the management of type 2 diabetes. It explains the mechanism of action of this medicine, its administration and dosing, the potential side effects, and its cautions and contraindications.
Verbatim abstract via PubMed 40383978 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.